Vial-and-syringe format
Effects on lipid profile T2DM patients have usually atherogenic dyslipidemia, depicted by high triglycerides and low-density lipoprotein cholesterol (LDL-C) levels, accompanied by low levels of high-density lipoprotein cholesterol (HDL-C)
Several markers of improved insulin sensitivity, including adiponectin, IGFBP-1, and IGFBP-2, significantly increased with one or more doses of tirzepatide
Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license
Key Benefits: Promotes weight loss and appetite regulation in research models